Published in Antimicrob Agents Chemother on December 15, 2008
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection. J Antimicrob Chemother (2010) 2.41
Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol (2011) 1.30
Mechanism of efavirenz influence on methadone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (2012) 1.04
Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci (2011) 0.98
The development and validation of a method using high-resolution mass spectrometry (HRMS) for the qualitative detection of antiretroviral agents in human blood. Clin Chim Acta (2014) 0.92
No evidence for induction of ABC transporters in peripheral blood mononuclear cells in humans after 14 days of efavirenz treatment. Antimicrob Agents Chemother (2010) 0.85
Toxic effects of maternal zearalenone exposure on uterine capacity and fetal development in gestation rats. Reprod Sci (2013) 0.82
Susceptibility of juvenile and adult blood-brain barrier to endothelin-1: regulation of P-glycoprotein and breast cancer resistance protein expression and transport activity. J Neuroinflammation (2012) 0.82
Drug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxis. PLoS One (2013) 0.81
Expression of Genes for Drug Transporters in the Human Female Genital Tract and Modulatory Effect of Antiretroviral Drugs. PLoS One (2015) 0.81
Interactions of tenofovir, Lamivudine, abacavir and Didanosine in primary human cells. Pharmaceutics (2011) 0.78
AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. BMC Res Notes (2011) 0.75
Modified halloysite nanotubes reduce the toxic effects of zearalenone in gestating sows on growth and muscle development of their offsprings. J Anim Sci Biotechnol (2016) 0.75
ABC transporters: from microorganisms to man. Annu Rev Cell Biol (1992) 19.49
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (2001) 3.45
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci (2000) 2.81
Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem (2001) 2.70
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx (2005) 2.44
Mechanism of active renal tubular efflux of tenofovir. Antimicrob Agents Chemother (2006) 2.41
Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther (2006) 2.23
An inventory of the human ABC proteins. Biochim Biophys Acta (1999) 2.22
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis. J Acquir Immune Defic Syndr (2006) 2.17
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr (2008) 2.04
Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. Biochem Biophys Res Commun (2003) 2.01
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
Functional involvement of multidrug resistance-associated protein 4 (MRP4/ABCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol Pharmacol (2006) 1.75
The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun (1995) 1.68
Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett (2006) 1.66
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel. Top HIV Med (2006) 1.65
In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther (2006) 1.60
Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol (2005) 1.52
In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Metab Dispos (2006) 1.50
Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol (2006) 1.43
Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal Biochem (2004) 1.39
Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res (2002) 1.39
Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther (2003) 1.39
Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2). Pharm Res (2007) 1.32
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol (2001) 1.30
Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol (2007) 1.26
Cellular export of drugs and signaling molecules by the ATP-binding cassette transporters MRP4 (ABCC4) and MRP5 (ABCC5). Drug Metab Rev (2005) 1.22
Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood (1998) 1.21
Transcriptional regulation and characterization of the promoter region of the human ABCC6 gene. J Invest Dermatol (2006) 1.17
Transport properties of the multidrug resistance-associated protein (MRP) in human tumour cells. FEBS Lett (1996) 1.16
The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr (2003) 1.12
Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res (2002) 1.11
ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages. Antivir Ther (2004) 1.10
Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int J Clin Pharmacol Ther (2000) 1.09
Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors (2003) 1.09
Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS (2003) 1.07
Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab Dispos (2006) 1.06
Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci (2005) 1.04
Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci (2001) 0.98
Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin Trials (2007) 0.97
Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci (2001) 0.95
Induction of proteins involved in multidrug resistance (P-glycoprotein, MRP1, MRP2, LRP) and of CYP 3A4 by rifampicin in LLC-PK1 cells. Eur J Pharmacol (2004) 0.90
The first once-daily single-tablet regimen for the treatment of HIV-infected patients. Drugs Today (Barc) (2007) 0.88
Selection and maintenance of multidrug-resistant cells. Methods Enzymol (1998) 0.87
Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology (2002) 0.85
Comparison of the induction of P-glycoprotein activity by nucleotide, nucleoside, and non-nucleoside reverse transcriptase inhibitors. Eur J Pharmacol (2007) 0.85
Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother (2003) 0.84
Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res (2006) 0.84
Cloning and Characterization of the Murine and Rat mrp1 Promoter Regions. Mol Pharmacol (2003) 0.83
Determination of P-gp and MRP1 expression and function in peripheral blood mononuclear cells in vivo. J Immunol Methods (2002) 0.80
New antiretroviral drugs in clinical use. Indian J Pediatr (2006) 0.80
Predictors of treatment failure during highly active antiretroviral therapy (racing trial). Eur J Med Res (2002) 0.79
Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther (2002) 0.79
Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J Pharm Pharmacol (2002) 0.78
Discordance of P-glycoprotein expression and function in acute leukemia. Adv Exp Med Biol (1999) 0.77
Oseltamivir carboxylate accumulation in a patient treated by haemodiafiltration and extracorporeal membrane oxygenation. Intensive Care Med (2010) 1.44
Peripheral blood mononuclear cell counting using a DNA-detection-based method. Anal Biochem (2004) 1.39
Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother (2010) 1.36
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells. Antimicrob Agents Chemother (2007) 1.35
Secretion of interleukin-1beta by astrocytes mediates endothelin-1 and tumour necrosis factor-alpha effects on human brain microvascular endothelial cell permeability. J Neurochem (2003) 1.35
Improved method for the simultaneous determination of d4T, 3TC and ddl intracellular phosphorylated anabolites in human peripheral-blood mononuclear cells using high-performance liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom (2002) 1.31
Concentrations of tenofovir and emtricitabine in breast milk of HIV-1-infected women in Abidjan, Cote d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2. Antimicrob Agents Chemother (2010) 1.26
Liquid chromatography-tandem mass spectrometry assays for intracellular deoxyribonucleotide triphosphate competitors of nucleoside antiretrovirals. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.20
In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab Dispos (2003) 1.12
Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2). Antimicrob Agents Chemother (2011) 1.09
Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol (2007) 1.08
A strategy for liquid chromatography/tandem mass spectrometric assays of intracellular drugs: application to the validation of the triphosphorylated anabolite of antiretrovirals in peripheral blood mononuclear cells. J Mass Spectrom (2003) 1.06
Effect of efavirenz on intestinal p-glycoprotein and hepatic p450 function in rats. J Pharm Pharm Sci (2005) 1.04
Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial. Clin Infect Dis (2003) 1.00
Relationship between HIV/Highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens. Clin Infect Dis (2010) 1.00
Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS (2004) 1.00
Cyclooxygenase-2 inhibitors prevent trinitrobenzene sulfonic acid-induced P-glycoprotein up-regulation in vitro and in vivo. Eur J Pharmacol (2010) 0.99
Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol (2006) 0.98
Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol (2005) 0.96
Development and validation of a liquid chromatographic/tandem mass spectrometric assay for the quantitation of nucleoside HIV reverse transcriptase inhibitors in biological matrices. J Mass Spectrom (2005) 0.92
In vitro evidence of dysregulation of blood-brain barrier function after acute and repeated/long-term exposure to TiO(2) nanoparticles. Biomaterials (2011) 0.91
Endothelial cell-derived bone morphogenetic proteins control proliferation of neural stem/progenitor cells. Mol Cell Neurosci (2008) 0.91
Brain and plasma riluzole pharmacokinetics: effect of minocycline combination. J Pharm Pharm Sci (2009) 0.91
Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses (2008) 0.91
Minocycline and riluzole brain disposition: interactions with p-glycoprotein at the blood-brain barrier. J Neurochem (2007) 0.91
Titanium dioxide nanoparticle impact and translocation through ex vivo, in vivo and in vitro gut epithelia. Part Fibre Toxicol (2014) 0.91
Effect of tumor necrosis factor-alpha and interferon-gamma on intestinal P-glycoprotein expression, activity, and localization in Caco-2 cells. J Pharm Sci (2004) 0.91
A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res (2002) 0.91
Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion model. Obstet Gynecol Int (2009) 0.90
Intestinal absorption of miltefosine: contribution of passive paracellular transport. Pharm Res (2007) 0.90
Visualization of ribonucleotide reductase catalytic oxidation establishes thioredoxins as its major reductants in yeast. Free Radic Biol Med (2007) 0.90
Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process. Lipids (2007) 0.90
Influence of tumor necrosis factor-alpha on the expression and function of P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochem Pharmacol (2003) 0.90
Development of a direct assay for measuring intracellular AZT triphosphate in humans peripheral blood mononuclear cells. Anal Chem (2002) 0.90
ABCG2- and ABCG4-mediated efflux of amyloid-β peptide 1-40 at the mouse blood-brain barrier. J Alzheimers Dis (2012) 0.89
Reduced intestinal absorption of dipeptides via PepT1 in mice with diet-induced obesity is associated with leptin receptor down-regulation. J Biol Chem (2009) 0.88
P-glycoprotein expression and function are increased in an animal model of amyotrophic lateral sclerosis. Neurosci Lett (2010) 0.88
Improvement of cefpodoxime proxetil oral absorption in rats by an oil-in-water submicron emulsion. Int J Pharm (2003) 0.88
HIV-1-induced production of endothelin-1 in an in vitro model of the human blood-brain barrier. Neuroreport (2002) 0.88
High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents Chemother (2008) 0.87
Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. J Acquir Immune Defic Syndr (2004) 0.87
Endothelin-1 reduces p-glycoprotein transport activity in an in vitro model of human adult blood-brain barrier. Cell Mol Neurobiol (2008) 0.87
Interactions between riluzole and ABCG2/BCRP transporter. Neurosci Lett (2009) 0.86
In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery. Mol Pharm (2011) 0.86
Stability of oxaliplatin solution. Ann Pharmacother (2009) 0.86
Long-term effect of leptin on H+-coupled peptide cotransporter 1 activity and expression in vivo: evidence in leptin-deficient mice. J Pharmacol Exp Ther (2007) 0.86
Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit (2012) 0.85
Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study). Antivir Ther (2004) 0.84
Association of thymidylate synthase gene polymorphisms with stavudine triphosphate intracellular levels and lipodystrophy. Antimicrob Agents Chemother (2011) 0.84
Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier. Pharm Res (2006) 0.84
Association between ABCB1 C3435T polymorphism and increased risk of cannabis dependence. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.84
Therapeutic efficiency of everolimus and lapatinib in xenograft model of human colorectal carcinoma with KRAS mutation. Fundam Clin Pharmacol (2012) 0.83
Population pharmacokinetics of everolimus in cardiac recipients: comedications, ABCB1, and CYP3A5 polymorphisms. Ther Drug Monit (2012) 0.83
Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferon-alpha in rats. J Pharm Pharmacol (2007) 0.83
MDR-1 C3435T polymorphism influences cyclosporine a dose requirement in liver-transplant recipients. Transplantation (2004) 0.83
Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2). Antimicrob Agents Chemother (2011) 0.83
Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin Cancer Res (2005) 0.83
Cyclooxygenase inhibitors down regulate P-glycoprotein in human colorectal Caco-2 cell line. Pharm Res (2008) 0.83
Contribution and limit of the model of perfused cotyledon to the study of placental transfer of drugs. Example of a protease inhibitor of HIV: nelfinavir. Eur J Obstet Gynecol Reprod Biol (2009) 0.82
Interaction between miltefosine and amphotericin B: consequences for their activities towards intestinal epithelial cells and Leishmania donovani promastigotes in vitro. Antimicrob Agents Chemother (2006) 0.82
Emtricitabine: Inhibitor and substrate of multidrug resistance associated protein. Eur J Pharm Sci (2008) 0.82
Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration. J Pharm Pharm Sci (2009) 0.81
Polymorphisms of Pyrimidine Pathway Enzymes Encoding Genes and HLA-B*40∶01 Carriage in Stavudine-Associated Lipodystrophy in HIV-Infected Patients. PLoS One (2013) 0.81
Modulation of intestinal barrier properties by miltefosine. Biochem Pharmacol (2005) 0.81
Intestinal inflammation induces adaptation of P-glycoprotein expression and activity. Biochem Pharmacol (2005) 0.81
Interleukin-2 treatment effect on imatinib pharmacokinetic, P-gp and BCRP expression in mice. Anticancer Drugs (2010) 0.80
Direct analysis of valsartan or candesartan in human plasma and urines by on-line solid phase extraction coupled to electrospray tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.80
Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther (2005) 0.80
Exposure to vehicle emissions results in altered blood brain barrier permeability and expression of matrix metalloproteinases and tight junction proteins in mice. Part Fibre Toxicol (2013) 0.80
Cetuximab increases concentrations of irinotecan and of its active metabolite SN-38 in plasma and tumour of human colorectal carcinoma-bearing mice. Fundam Clin Pharmacol (2014) 0.79
Is stavudine triphosphate a natural metabolite of zidovudine? Antimicrob Agents Chemother (2006) 0.79
Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. Eur J Drug Metab Pharmacokinet (2011) 0.79
Development of an assay method for the detection and quantification of protease and non-nucleoside reverse transcriptase inhibitors in plasma and in peripherical blood mononuclear cells by liquid chromatography coupled with ultraviolet or tandem mass spectrometry detection. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.79
Therapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacy. ACS Nano (2014) 0.79
Effect of interleukin-2 on intestinal P-glycoprotein expression and functionality in mice. J Pharmacol Exp Ther (2002) 0.79
Rosiglitazone and metformin have opposite effects on intestinal absorption of oligopeptides via the proton-dependent PepT1 transporter. Mol Pharmacol (2011) 0.78
Dodecyl creatine ester and lipid nanocapsule: a double strategy for the treatment of creatine transporter deficiency. Nanomedicine (Lond) (2014) 0.78
Effect of oil-in-water submicron emulsion surface charge on oral absorption of a poorly water-soluble drug in rats. Drug Deliv (2008) 0.78
Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat. J Photochem Photobiol B (2006) 0.78
Irinotecan and temozolomide brain distribution: a focus on ABCB1. Cancer Chemother Pharmacol (2014) 0.78
A new UPLC-MS/MS method for the determination of irinotecan and 7-ethyl-10-hydroxycamptothecin (SN-38) in mice: application to plasma and brain pharmacokinetics. J Pharm Biomed Anal (2012) 0.78
Potentiation of mivacurium blockade by low dose of pancuronium: a pharmacokinetic study. Anesthesiology (2003) 0.78
Modification of the P-glycoprotein dependent pharmacokinetics of digoxin in rats by human recombinant interferon-alpha. Pharm Res (2005) 0.78
Pharmacokinetics of propofol administered by target-controlled infusion to alcoholic patients. Anesthesiology (2003) 0.78
Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells. J Pharm Pharmacol (2002) 0.78
MDR1A (ABCB1)-deficient CF-1 mutant mice are susceptible to cerebral malaria induced by Plasmodium berghei ANKA. J Parasitol (2008) 0.77
Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse. Eur J Pharm Sci (2005) 0.77
Regulation of the oligopeptide transporter, PEPT-1, in DSS-induced rat colitis. Dig Dis Sci (2007) 0.77
MDR1 polymorphism role in patients treated with cetuximab and irinotecan in irinotecan refractory colorectal cancer. Med Oncol (2009) 0.77
Disposition of Delta tetrahydrocannabinol in CF1 mice deficient in mdr1a P-glycoprotein. Addict Biol (2008) 0.77
Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. Am J Health Syst Pharm (2009) 0.77
Disturbed intestinal nitrogen homeostasis in a mouse model of high-fat diet-induced obesity and glucose intolerance. Am J Physiol Endocrinol Metab (2014) 0.77